Display Settings:

Format

Send to:

Choose Destination
    Expert Opin Biol Ther. 2008 Oct;8(10):1485-93.

    TGF-beta3: A promising growth factor in engineered organogenesis.

    Source

    Nanyang Technological University, School of Chemical and Biomedical Engineering, Division of Bioengineering, 70 Nanyang Drive, N1.3-B2-13, Singapore 637457, Republic of Singapore.

    Abstract

    BACKGROUND:

    Engineered organogenesis is one of the most challenging areas on the cutting edge of regenerative medicine. Growth factors can affect cell proliferation, migration and differentiation profoundly, and thus play a critical role in tissue regeneration. TGF-betas produce a wide range of effects in different cells and tissues. TGF-beta3 is relatively recently discovered and studied.

    OBJECTIVE:

    To provide a broader understanding of the current state of TGF-beta3 in engineered osteogenesis, chondrogenesis, palate development, scar-free wound healing, odontogenesis and neurogenesis.

    METHODS:

    This review summarizes studies that explore or apply TGF-beta3 for organogenesis with engineering methodology and a regenerative medical perspective.

    RESULTS/CONCLUSION:

    TGF-beta3 has proven to be a competent growth factor in engineered organogenesis in vitro. In recent years, using TGF-beta3, more and more in vivo studies have yielded significant therapeutic achievements in animal models, which bear much promise for future medical application.

    PMID:
    18774917
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Informa Healthcare

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk